CRISPR Therapeutics AG (CRSP US, +N, 18-Jul-25)
Simeon George (Non-Executive since April 2015) purchased 989,812 shares, spending $51.5 million on July 16th at $52.03, more than doubling his position. The purchase is made indirectly on behalf of SR One Capital Management, a transatlantic biotech venture capital firm where he serves as Managing Partner (joined 2007). SR One was previously the venture capital arm of GSK and spun out in 2020.
Their only previous transactions were subscriptions for $931,000 at $14 in October 2016 and $75 million at $71.50 in February 2024. This appears to be their first open market purchase, just slightly below the prior day’s close. We are also surprised to see the purchase, assuming the company is in a closed period with their results expected around the 10th of August. There has been no announcement of a capital raising by the company, although that is a possible explanation.
We are ranking the stock +N (notable and positive signal).
If you want the Stock of the Week with insider buying stocks information and analysis in your email, don’t forget to subscribe! Follow us on LinkedIn and Twitter
Check our Signals Performance and if you want to know more about this Signals Service, please, email us at sales_admin@smartinsider.com or fill in the Contact Us form here.
